Patrícia Xavier Santi

Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study

Tadeusz Robak, Jie Jin, Halyna Pylypenko et al. · The Lancet Oncology · 2018 · 132 citations

Hematological Malignancy, Frontline Bortezomib, Lymphoid Neoplasia +13

Efficacy and safety of ABP 980 compared with reference trastuzumab in women with HER2-positive early breast cancer (LILAC study): a randomised, double-blind, phase 3 trial

Gϋnter von Minckwitz, Marco Colleoni, Hans‐Christian Kolberg et al. · The Lancet Oncology · 2018 · 97 citations

Breast Oncology, Lilac Study, Medicine +7

Ratio Between Positive Lymph Nodes and Total Dissected Axillaries Lymph Nodes as an Independent Prognostic Factor for Disease-Free Survival in Patients With Breast Cancer

Luciano J. Costa, Heloisa P. Soares, Heloísa Amaral Gaspar et al. · American Journal of Clinical Oncology · 2004 · 50 citations

Surgical Oncology, Breast Oncology, Medicine +13

<i>Uncaria tomentosa</i> (Cat's Claw) Improves Quality of Life in Patients with Advanced Solid Tumors

Larissa Carvalho Lopes de Paula, Fernando Luiz Affonso Fonseca, Fábio Ferreira Perazzo et al. · The Journal of Alternative and Complementary Medicine · 2014 · 27 citations

Adjuvant treatment delay in breast cancer patients

Damila Cristina Trufelli, Leandro Luongo Matos, Patrícia Xavier Santi et al. · Revista da Associação Médica Brasileira · 2015 · 25 citations · Full text